Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near‐Real‐Time Monitoring Program in Italy.

Slides:

Advertisements

Similar presentations

Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target

Advertisements

Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

Case study - patient presenting with newly diagnosed NVAF with prior CAD Full Prescribing Information is provided at the end of this presentation EUAPI581k;

Gli anticoagulanti diretti nel mondo reale

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effects of Habitual Coffee Consumption on Cardiometabolic.

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Practical Management of Anticoagulation in Patients.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.

Volume 149, Issue 6, Pages (June 2016)

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Table 1. Baseline Characteristics of the 36,636 Study Subjects

2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation Chern-En Chiang, Tsu-Juey.

How Do We Incorporate Patient Perspectives Into Clinical Trial Design?

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

Should paroxysmal atrial fibrillation be treated during cardiac surgery? Patrick M. McCarthy, MD, Adarsh Manjunath, BA, Jane Kruse, RN, BSN, Adin-Cristian.

by Kueiyu Joshua Lin, Daniel E. Singer, Robert J

Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Chronic Total Coronary Occlusion With Well‐Developed Collaterals by Se Yeon Choi,

Circ Cardiovasc Interv

Ahead of the Curve by Alun D. Hughes Hypertension Volume 64(5):

Circ Cardiovasc Qual Outcomes

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal Gregory.

by Anuj Shah, Anand Shewale, Corey J. Hayes, and Bradley C. Martin

by John T. Wilkins, Hongyan Ning, Neil J. Stone, Michael H

Click here for title Click here for subtitle

2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Laurent Macle, MD, John Cairns, MD, Kori.

Oral Anticoagulation and Preventing Stent Thrombosis

Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation Lena Rivard, MD, MSc, Paul Khairy, MD,

Nat. Rev. Cardiol. doi: /nrcardio

Volume 15, Issue 1, Pages (January 2018)

James H. O’Keefe, MD, Salman K. Bhatti, MD, Ata Bajwa, MD, James J

FAERS death cases (all years) for NOACs versus warfarin.

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Ashish Shukla et al. JACEP 2015;1:41-51

Dileep Raman et al. JACEP 2017;3:

Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey by Claudio Cimminiello, Robert Hatala, Sami Pakarinen, Hernan.

Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey by Claudio Cimminiello, Robert Hatala, Sami Pakarinen, Hernan.

Should paroxysmal atrial fibrillation be treated during cardiac surgery? Patrick M. McCarthy, MD, Adarsh Manjunath, BA, Jane Kruse, RN, BSN, Adin-Cristian.

David J.A. Jenkins et al. JACC 2018;71:

John A. Bittl et al. JACC 2016;68:

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Atrial fibrillation and the risk of incident dementia: A meta-analysis

Björn Redfors et al. JACEP 2017;j.jacep

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Maneesh Sud et al. JCHF 2017;5:

The American Journal of Medicine

Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation

Erratum Canadian Journal of Cardiology

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

Associations between type of MI and incident HF

Presentation data from US VICTORY Consortium

Zachary L. Steinberg et al. JACC 2017;69:

Adjusted ORs of AF according to time since bereavement versus non-bereaved in a population from Denmark between 1995 and * *ORs are adjusted for.

Pamela E. Scott et al. JACC 2018;71:

Forest plot illustrating the risk ratio of any bleeding and GRADE assessment. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI,

Increase of physical activity over time associated with lower HF risk

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Figure 8. Stroke prevention strategy in patients with AF

Gianluigi Savarese et al. JCHF 2016;4:

Forest plot illustrating the risk ratio of major bleeding

Forest plot illustrating the risk ratio of myocardial infarction

Forest plot illustrating risk ratio of stent thrombosis

Presentation transcript:

Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near‐Real‐Time Monitoring Program in Italy by Flavia Mayer, Ursula Kirchmayer, Paola Coletta, Nera Agabiti, Valeria Belleudi, Giovanna Cappai, Mirko Di Martino, Sebastian Schneeweiss, Marina Davoli, and Elisabetta Patorno J Am Heart Assoc Volume 7(6):e008034 March 10, 2018 © 2018 Flavia Mayer et al.

Cohort selection. Cohort selection. AF indicates atrial fibrillation; DOAC, direct oral anticoagulants; ICD‐9‐CM, the International Classification of Diseases, 9th Revision, Clinical Modification; PS, propensity score; VKA, vitamin K antagonists. Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034 © 2018 Flavia Mayer et al.

Mortality—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists. Mortality—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists. Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034 © 2018 Flavia Mayer et al.

Cardiovascular mortality—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists. Cardiovascular mortality—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists. Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034 © 2018 Flavia Mayer et al.

Acute myocardial infarction—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists. Acute myocardial infarction—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists. Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034 © 2018 Flavia Mayer et al.

Ischemic stroke—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists. Ischemic stroke—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists. Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034 © 2018 Flavia Mayer et al.

Hemorrhagic stroke—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists. Hemorrhagic stroke—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists. Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034 © 2018 Flavia Mayer et al.

Gastrointestinal bleeding—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists. Gastrointestinal bleeding—sequential analysis of new users of DOACs vs VKAs—HR and 95% CI. CI indicates confidence interval; DOAC, direct oral anticoagulants; HR, hazard ratio; PS, propensity score; VKA, vitamin K antagonists. Flavia Mayer et al. J Am Heart Assoc 2018;7:e008034 © 2018 Flavia Mayer et al.